Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Davidson

Showing results (51-60 of 300) with videos related to

Pageof 30
Sort By:
The American Journal of Cardiology|October 16, 2012
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. IntroductionMichael H Davidson
The American Journal of Cardiology|August 16, 2005
Management of dyslipidemia in patients with complicated metabolic syndromeMichael H Davidson
ACP Journal Club|September 2, 2005
Atorvastatin at 80 mg/d reduced major cardiovascular events more than atorvastatin at 10 mg/d in stable coronary heart diseaseMichael H Davidson
Journal of Clinical Lipidology|May 7, 2013
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reductionMichael H Davidson
The American Journal of Cardiology|March 20, 2002
Strategies to improve Adult Treatment Panel III guideline adherence and patient complianceMichael H Davidson
The Journal of Family Practice|November 7, 2009
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a timeMichael H Davidson
Expert Opinion on Investigational Drugs|January 5, 2002
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemiaMichael H Davidson
The American Journal of Cardiology|July 25, 2008
Introduction. U.S. incidence of coronary artery diseaseMichael H Davidson
Ebiomedicine|July 3, 2015
Beta-2 Agonism: A Potential Therapeutic Target for DyslipidemiaMichael H Davidson
Expert Opinion on Investigational Drugs|May 29, 2003
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemiaMichael H Davidson
Pageof 30

Showing results (51-60 of 300) with videos related to

Sort By:
Pageof 30
The American Journal of Cardiology|October 16, 2012
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. IntroductionMichael H Davidson
The American Journal of Cardiology|August 16, 2005
Management of dyslipidemia in patients with complicated metabolic syndromeMichael H Davidson
ACP Journal Club|September 2, 2005
Atorvastatin at 80 mg/d reduced major cardiovascular events more than atorvastatin at 10 mg/d in stable coronary heart diseaseMichael H Davidson
Journal of Clinical Lipidology|May 7, 2013
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reductionMichael H Davidson
The American Journal of Cardiology|March 20, 2002
Strategies to improve Adult Treatment Panel III guideline adherence and patient complianceMichael H Davidson
The Journal of Family Practice|November 7, 2009
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a timeMichael H Davidson
Expert Opinion on Investigational Drugs|January 5, 2002
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemiaMichael H Davidson
The American Journal of Cardiology|July 25, 2008
Introduction. U.S. incidence of coronary artery diseaseMichael H Davidson
Ebiomedicine|July 3, 2015
Beta-2 Agonism: A Potential Therapeutic Target for DyslipidemiaMichael H Davidson
Expert Opinion on Investigational Drugs|May 29, 2003
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemiaMichael H Davidson
Pageof 30